Adicet Bio (ACET) vs CervoMed (CRVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adicet Bio (ACET) has outperformed CervoMed (CRVO) over the past year, losing 77.8% versus a loss of 83.6%. Over five years, CRVO leads with a -95.0% price change compared with -98.6% for ACET. CervoMed is the larger company by market cap ($22.1 million vs $20.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | CRVO |
|---|---|---|
| Share price | $2.14 | $1.46 |
| Market cap | $20.03M | $22.09M |
| 1-day change | -13.01% | +9.77% |
| YTD return | -74.58% | -81.52% |
| 1-year return | -77.78% | -83.56% |
| 5-year return | -98.58% | -95.01% |
| EPS (TTM) | $-7.53 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.01M |
| Revenue growth (YoY) | — | -58.86% |
| Net income (latest FY) | $-116.80M | $-26.97M |
| Operating margin | — | -706.22% |
| Net margin | — | -673.06% |
| 52-week high | $11.15 | $10.00 |
| 52-week low | $2.12 | $1.27 |
| Distance from 52-week high | -80.81% | -85.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1527.57% | +954.79% |
| Average volume | 271.05K | 489.10K |
| Shares outstanding | 9.36M | 15.13M |
| Employees | 102 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ACET vs CRVO FAQ
Which is bigger, Adicet Bio or CervoMed?
CervoMed (CRVO) is larger, with a market capitalization of $22.09M compared with $20.03M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or CRVO?
ACET returned -77.78% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and CervoMed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.